PhD Domingo Gargallo-Viola

Co-founder and Chief Scientific Officer of ABAC Therapeutics, a leader in pathogen-specific antibiotics formerly part of the Ferrer International Group based in Spain. Domingo has over 30 years of experience in anti-infective drug discovery and development. At ABAC Therapeutics, he focuses on the discovery and development of pathogen-specific, narrow-spectrum antibiotics with a novel mechanism of action for the treatment of severe and life-threatening infections caused by multi-resistant organisms.Prior to joining Laboratorios Ferrer in 2008 as Manager of Infectious Diseases and Director of Pharmacology, Toxicology and Safety Pharmacology, he was Director of Drug Discovery Biology at GSK. Domingo spent 18 years at GSK, leading the GSK-Medicines for Malaria Venture Support Group and several projects that led to the discovery of first-in-class drug candidates. He was also head of GSK’s Mycology and Chemotherapy Departments at the Tres Cantos Research Center in Spain. Domingo is currently President of the Association for the Discovery of New Antibiotics in Spain and Vice President of the Spanish Network for the Development of Alternative Methods in Animal Experimentation.